

Supplemental Materials

Conflict of Interest: Dr. Tang received research funding from Neurologix Inc. during the conduct of the study. Dr. LeWitt received research funding from Neurologix Inc. during the conduct of the study. Dr. Rezaei is a board member and a shareholder at Autonomic Technologies Inc. and Neurotechnology Innovations Translator. Dr. Leehey received research funding from the National Institute of Neurological Disorders and Stroke and Neurologix Inc. during the conduct of the study; and has received research funding from Colorado Department of Public Health and Environment, Adamas Pharmaceuticals, US WorldMeds LLC, Pharma Two B, and The Michael J. Fox Foundation for Parkinson's Research outside the submitted work. Dr. Ojemann received research funding from Neurologix Inc. during the conduct of the study; has received consulting fees from Medtronic Inc.; is a DSMB member at Voyager Therapeutics Inc.; and has been a speaker for Alpha Omega Industries Inc. Dr. Flaherty received research funding from Neurologix Inc. during the conduct of the study. Dr. Kostyk's institution received funding from Neurologix Inc. (for salary support of study staff other than Dr. Kostyk) during the conduct of the study. Dr. Siddiqui received research funding from Neurologix Inc. during the conduct of the study; has received honoraria for consulting from Medtronic Inc. and AbbVie; has received scientific advisory board member fees from Merz Pharma; and has received research funding from Boston Scientific, Synapse, and Cynapsus Therapeutics outside the submitted work. Dr. Tatter received research funding from Neurologix Inc. during the conduct of the study. Dr. Schwalb received research funding from Neurologix Inc. during the conduct of the study; and has received research funding from Boston Scientific and Medtronic Inc. outside the submitted work. Dr. Poston received research funding from Neurologix Inc. during the conduct of the study; and has received research funding from AstraZeneca, The Michael J. Fox Foundation for Parkinson's Research, and the National Institutes of Health outside the submitted work. Dr. Henderson has received fellowship support paid to his institution from Medtronic Inc.; has received consulting fees from Nevro Corp. and Circuit Therapeutics; and has received medical advisory board member fees from Circuit Therapeutics, Enspire DBS Therapy Inc., and NeuroPace. Dr. Kurlan received research funding from the University of Rochester during the conduct of the study. Dr. Richard received research funding from Neurologix Inc. during the conduct of the study. Dr. Eidelberg has received scientific advisory board member fees from The Michael J. Fox Foundation for Parkinson's Research; is a coinventor of the patents re: Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same (United States Patent No. 5,632,276 and No. 5,873,823); and has received research funding from the National Institutes of Health (NINDS, NIDCD, NIAID) and the Dana Foundation outside the submitted work. Dr. During received research funding and personal fees from Neurologix Inc. during the conduct of the study; and is a coinventor of the patent re: Glutamic acid decarboxylase (GAD) based delivery systems (United States Patent No. 7,695,959 B2). Dr. Kaplitt received research funding and personal fees from Neurologix Inc. during the conduct of the study; and is a coinventor of the patent re: Glutamic acid decarboxylase (GAD) based delivery systems (United States Patent No. 7,695,959 B2). Dr. Feigin has received research funding from Voyager Therapeutics Inc. outside the submitted work. All other authors have declared that no conflict of interest exists.